A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2492-2496

  Sanati, Homayoon ^a   Belanger, Paul ^a   Fratti, Rutilio ^a   Ghannoum, Mahmoud ^b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24 METHYLENEDIHYDROLANOSTEROL; 4,14 DIMETHYLZYMOSTEROL; ANTIFUNGAL AGENT; ERGOSTEROL; FLUCONAZOLE; LANOSTEROL DERIVATIVE; SQUALENE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STEROL SYNTHESIS; STRAIN DIFFERENCE;

EID: 0030704329     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2492     Document Type: Article

References (27)

1. Anaissie, E. J. 1992. Opportunistic mycoses in the immunocompromised hosts: experience in a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1):43-53.
2. Arndt, C. A. S., T. J. Walsh, C. L. McCully, F. M. Balis, P. A. Pizzo, and D. G. Poplack. 1988. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J. Infect. Dis. 157:178-180.
3. + from Candida species. J. Antimicrob. Chemother. 11:381-383.
4. R) Candida albicans strains, abstr. F.75. In Abstracts of the 96th General Meeting of the American Society for Microbiology 1996. American Society for Microbiology, Washington, D.C.
5. Bodey, G. P. 1988. Fungal infections in cancer patients. Ann. N.Y. Acad. Sci. 544:431-442.
6. + release. J. Gen. Microbiol. 119:245-251.
7. Denning, D., A. del Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Youren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
9. Ghannoum, M. A. 1988. Mechanisms potentiating Candida infections: a review. Mycoses 31:543-557.
10. Ghannoum, M. A., N. A. Moussa, P. Whittaker, I. Swairjo, and K. H. Abu-Elteen. 1992. Subinhibitory concentration of octenidine and pirtenidine: influence on the lipid and sterol contents of Candida albicans. Chemotherapy (Basel) 38:46-56.
11. Ghannoum, M. A., B. Spellberg, A. S. Ibrahim, J. A. Ritchie, B. Currie, E. D. Spitzer, J. E. Edwards, and A. Casadevall. 1994. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob. Agents Chemother. 38:2029-2033.
12. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Hitchcock, C. A., and P. J. Whittle. 1993. Chemistry and mode of action of fluconazole, p. 183-197. In J. W. Rippon and R. A. Fromtling (ed.), Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker, Inc. New York, N.Y.
14. Jezequel, S. G., M. Clark, S. Cole, K. E. Evans, and P. Wastall. 1995 UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics, abstr. F76. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Marriott, M. S. 1975. Isolation and characterization of plasma membranes from the yeast and mycelial forms of Candida albicans. J. Gen. Microbiol. 86:115-132.
16. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast; tentative standard M27T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Pancaldi, S., G. Dall'Olio, F. Poli, and M. P. Fasulo. 1994. Stimulation of autophagic activity in blastospores of Candida albicans exposed in vitro to fluconazole. Microbios 80:55-61.
18. Pesti, M., J. M. Campbell, and J. F. Peberdy. 1981. Alterations of ergosterol content and chitin synthase activity in Candida albicans. Curr. Microbiol. 5:187-190.
19. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in patients with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
20. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Saf. 5:94-108.
21. Selik, R. M., E. T. Starcher, and J. W. Curran. 1987. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1: 175-182.
22. Stern, J. J., B. J. Hartman, P. Sharkey, V. Rowland, K. Squires, H. Murray, and R. Graybill. 1988. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am. J. Med. 85:477-480.
23. Sud, I. J., and D. S. Feingold. 1981. Mechanisms of action of the antimycotic imidazoles. J. Investig. Dermatol. 76:438-441.
24. Sud, I. J., and D. S. Feingold. 1981. Heterogeneity of action mechanisms among antimycotic imidazoles. Antimicrob. Agents Chemother. 20:71-74.
25. Vanden Bossche, H., P. Marichal, L. le Jeune, M.-C. Coene, J. Gorrens, and W. Cools. 1993. Effects of itraconazole on cytochrome P-450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob. Agents Chemother. 37:2101-2105.
26. Vandenheuvel, F. A., and A. S. Court. 1968. Reference high-efficiency non-polar packed column for the gas-liquid chromatography of nanogram amounts of sterols. Part I. Retention time data. J. Chromatogr. 38:439-459.
27. Wey, S., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.